SCHIZOPHRENIA IS A FACTOR INCREASING THE RISKS OF METABOLIC SYNDROME DEVELOPMENT. FINDINGS OF THE RESEARCH INVOLVING PAIR SELECTION METHOD

  • Authors: Neznanov NG1,2, Martynikhin IA2, Tanyansky DA3, Rotar OP4, Solntsev VN4, Sokolyan NA1, Konradi AO4, Denisyenko AD3
  • Affiliations:
    1. St.-Petersburg Bekhterev Psychoneurological Research Institute
    2. St.-Petersburg State Medical University named after I. P. Pavlov
    3. Institute of The Experimental Medicine of North-West Branch of Russian Academy of Medical Sciences
    4. Almazov Federal Blood, Heart, And Endocrinology Centr
  • Issue: Vol 13, No 3 (2013)
  • Pages: 90-96
  • Section: Articles
  • URL: https://journals.eco-vector.com/MAJ/article/view/9851
  • DOI: https://doi.org/10.17816/MAJ13390-96
  • Cite item

Abstract


The aim was to evaluate the prevalence of metabolic syndrome and its components in patients with schizophrenia and to compare the frequency of these metabolic disorders with mental healthy subjects. Methods. 138 schizophrenic patients and 138 bank employees controls, matched by sex, age and body mass index, we enrolled to this study. In both groups plasma concentrations of lipids, glucose, insulin, cortisol, prolactin, leptin and adiponectin were determined. Results. In comparison with controls patients with schizophrenia had significantly higher frequency of metabolic syndrome and such its components as abdominal obesity, hypertriglyceridemia and low level of high density lipoprotein cholesterol. Schizophrenic patients had lower concentrations of glucose, total and high density lipoprotein cholesterol, while insulin and triglycerides content was higher in this group. Conclusions. Patients with schizophrenia have high risk of metabolic syndrome, which can predispose them to development of cardiovascular disorders and decline of life longevity. Metabolic syndrome in patients with schizophrenia has some special features, which can be a result of influence of specific risk factors on these subjects.

Full Text

Restricted Access

About the authors

N G Neznanov

St.-Petersburg Bekhterev Psychoneurological Research Institute; St.-Petersburg State Medical University named after I. P. Pavlov

Email: spbinstb@bekhterev.ru

I A Martynikhin

St.-Petersburg State Medical University named after I. P. Pavlov

D A Tanyansky

Institute of The Experimental Medicine of North-West Branch of Russian Academy of Medical Sciences

O P Rotar

Almazov Federal Blood, Heart, And Endocrinology Centr

V N Solntsev

Almazov Federal Blood, Heart, And Endocrinology Centr

N A Sokolyan

St.-Petersburg Bekhterev Psychoneurological Research Institute

A O Konradi

Almazov Federal Blood, Heart, And Endocrinology Centr

A D Denisyenko

Institute of The Experimental Medicine of North-West Branch of Russian Academy of Medical Sciences

References

  1. Brown S. Excess mortality of schizophrenia: a meta-analysis // Brit. J. of Psychiatry.-1997.- Vol. 171.- Р. 502-508.
  2. Newman S. C., Bland R. C. Mortality in a cohort of patients with schizophrenia: a record linkage study // Can. J. Psychiatry.- 1991.- Vol. 36 (4).- Р. 239-245.
  3. Osby U., Correia N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm county.- Sweden, 2000.-Vol. 45(1-2).- Р. 21-28.
  4. McEvoy J., Meyer J., Goff D. et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research.- 2005.- Vol. 80 (1).- Р. 19-32.
  5. Ford E. S., Giles W. H., Dietz W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey // JAMA.- 2002.- Vol. 287.- Р. 356-359.
  6. Heiskanen T., Niskanen L., Lyytikainen R. et al. Metabolic syndrome in patients with schizophrenia // J. of Clinical Psychiatry.- 2003.-Vol. 64.- Р. 575-579.
  7. Cohn T., Prud homme D., Streiner D. et al. Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome // Can. J. Psychiatry.- 2004;49.- Р. 753-760.
  8. De Hert M., van Winkel R., Van Eyck D. et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study // Clin. Pract. Epidemol. Ment. Health.- 2006.- Vol. 27.- Р. 14.
  9. Капилетти С. Г., Мосолов С. Н., Шафаренко А. А. Частота метаболических расстройств у больных шизофренией, получающих антипсихотическую терапию. Материалы Общероссийской конференции Реализация подпрограммы «Психические расстройства» Федеральной целевой программы «Предупреждение и борьба с социально-значимыми заболеваниями (2007-2011)» Москва 28-30 октября 2008.- М., 2008.- С. 414-416.
  10. Горобец Л. Н. Нейроэндокринные дисфункции и нейролептическая терапия.- М.: Медпрактика-М, 2007.- 312 с.
  11. Незнанов Н. Г., Мартынихин И. А., Соколян Н. А. Распространенность метаболического синдрома среди госпитализированных больных параноидной формой шизофрении в Санкт-Петербурге // Тезисы научно-практической конференции «Актуальные проблемы оказания психиатрической помощи в Северо-Западном регионе Российской Федерации».- СПб., 2008.- С. 147-148.
  12. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, 2006, www.idf.org/metabolic_syndrome, website of the International Diabetes Federation.
  13. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) // JAMA.- 2001.- Vol. 285.- Р. 2486-2497.
  14. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes // J. Clin. Psychiatry.- 2004.- Vol. 65.- Р. 267-272.
  15. Newcomer J. W., Nasrallah H. A., Loebel A. D. The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists // J. Clin. Psychopharmacol.- 2004.- Vol. 24 (5 suppl. 1).- Р. S1-S6.
  16. Ryan M. С. M., Collins P., Thakore J. H. Impaired fasting glucose tolerance in first-episode, drug naive patients with schizophrenia // Amer. J. of Psychiatry.- 2003.- Vol. 160.- Р. 284-289.
  17. Thakore J. H., Vlahoos J., MartinA. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia // Int. J. of Obesity Related Metabolic Disorders.- 2002.- Vol. 26.- Р. 137-141.
  18. Bushe C., Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia // Brit. J. of Psychiatry.- 2004.-Vol. 18, № 4 (suppl. 47).- Р. 67-71.
  19. La Y. J., Wan C. L., Zhu H. et al. Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients // J. Neural. Transm.- 2007.-Vol. 114 (5).- Р. 657-663.
  20. Huang J., Wang L., Prabakaran S. et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. // Molecular Psychiatry advance online publication 16 Chtober 2007.- doi: 10.1038/sj.mp.4002108

Statistics

Views

Abstract - 46

PDF (Russian) - 2

Cited-By


PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2013 Neznanov N.G., Martynikhin I.A., Tanyansky D.A., Rotar O.P., Solntsev V.N., Sokolyan N.A., Konradi A.O., Denisyenko A.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies